ScreenerHero

REGN Regeneron Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · regeneron.com
726.84USD+0.05%Mkt Cap: 74.79B $P/E: 17.96

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammator…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD
TWST
Twist Bioscience Corporation
$13.59BUSD

Key Statistics

Company
Market Cap74.79B USD
Enterprise Value68.13B USD
Revenue (TTM)15.53B USD
Gross Profit12.24B USD
Net Income (TTM)4.50B USD
Revenue/Share150.31 USD
Last Price726.84 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees15.4K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)17.96
P/E (Forward)11.96
PEG1.25
EV/EBITDA14.49
EV/Revenue4.39
P/S4.87
P/B2.33
EPS (TTM)40.44
EPS (Forward)61.47
52W Range
541.0058% of range859.34
52W High859.34 USD
52W Low541.00 USD
Profitability
Gross Margin85.35%
Oper. Margin33.11%
EBITDA Margin30.27%
Profit Margin31.41%
ROE14.41%
ROA11.11%
Growth
Revenue Growth16.70%
Earnings Growth-4.50%
Cash Flow & Leverage
Operating CF4.98B USD
CapEx (TTM)1.21B USD
FCF Margin19.73%
FCF Yield4.10%
Net Debt-5.29B USD
Net Debt/EBITDA-1.12
Balance Sheet
Debt/Equity0.09
Current Ratio3.33
Quick Ratio2.63
Book Value/Sh316.11 USD
Cash/Share80.06 USD
Dividends
Fwd Div Rate3.76 USD
Trail. Div Rate3.64 USD
Div. Yield0.51%
5Y Avg Yield—
Payout Ratio9.00%
Ex-Div DateAug 18, 2026
Pay DateAug 31, 2026
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)853.19 USD
Upside (mean)+17.4%
Target Range730.00 USD – 1030.00 USD
730.00+17.4% to mean1030.00
# Analysts26
Ownership
Shares Out.101.14M
Float95.85M
Insiders2.08%
Institutions93.54%
Short Interest
Short Ratio4.0d
Short % Float2.60%
Short % Out.2.45%
Shares Short2.53M
Short (prev mo.)2.40M
Technical
SMA 50784.86 (-7.4%)
SMA 200736.04 (-1.3%)
Beta0.19
S&P 52W Chg14.58%
Avg Vol (30d)694.30K
Avg Vol (10d)770.36K
Technical Indicators
RSI (14)35.3
MACD-11.6848
MACD Signal-1.5371
MACD Hist.-10.1477
BB Upper855.88 USD
BB Middle785.82 USD
BB Lower715.76 USD
BB Width17.83%
ATR (14)22.09 USD
Vol Ratio (20d)0.93x